Concepedia

Andrew Lim

AL

Statistics

Publications

7

Citations

722

H-Index

7

Active since

2014

Affiliations

Institut Català d'Oncologia(Current)

Sanofi (France)

University College London

Charles University

Université de Lille

Andrew Lim is an author at Institut Català d'Oncologia specializing in medicine, pharmacology, and multiple myeloma treatment.

Publications per year

2014–2022

7

Publications

7

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Philippe Moreau, Meletios Α. Dimopoulos, Joseph Mıkhael et al. · The Lancet · 2021 · 380 citations

Medicine, Pharmacology, Pharmacotherapy +12

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Fredrik Schjesvold, Albert Oriol, Lionel Karlin et al. · The Lancet Haematology · 2019 · 242 citations · Full text

Medicine, Oncology, Pharmacology +11

MA 13.07 A Randomized Trial of SABR vs Conventional Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: TROG09.02 (CHISEL)

Daniel Ball, T. Mai, Shalini Vinod et al. · Journal of Thoracic Oncology · 2017 · 31 citations · Full text

Medicine, Oncology, Radiation Oncology +12

Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: <scp>IKEMA</scp> subgroup analysis

Ivan Špıčka, Philippe Moreau, Thomas G. Martin et al. · European Journal Of Haematology · 2022 · 24 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis

Thierry Façon, Philippe Moreau, Thomas G. Martin et al. · Hematological Oncology · 2022 · 18 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

1–5 of 7